BRIEF-I-MAB Announces Portfolio Prioritization Of Givastomig As Lead Clinical Program

Reuters
06 Jan

Jan 6 (Reuters) - I-Mab :

* I-MAB ANNOUNCES PORTFOLIO PRIORITIZATION OF GIVASTOMIG (CLDN18.2 X 4-1BB BISPECIFIC ANTIBODY) AS LEAD CLINICAL PROGRAM

* I-MAB - CASH BALANCE OF $184.4 MILLION AS OF SEPT 2024, EXPECTED TO SUPPORT OPERATIONS INTO 2027

Source text: Further company coverage:

((Reuters.Brief@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10